Defective viruses are viral particles with genetic abnormalities or mutations that render them unable to complete their life cycle or replicate efficiently. These viruses often lack essential genes required for replication or exhibit structural defects in their genetic material. Defective viruses may arise naturally during the course of viral infections or can be intentionally engineered for therapeutic purposes. In some cases, defective viruses can interfere with the replication of their fully functional counterparts through a phenomenon known as viral interference. This interference may limit the spread of the functional virus and impact the severity of the infection. Defective viruses have been studied in the context of oncolytic virotherapy, where they are designed to selectively infect and destroy cancer cells while sparing normal cells. These engineered defective viruses can replicate in cancer cells, leading to their destruction, and may be used as potential treatments for certain types of cancers. Understanding defective viruses provides insights into viral evolution, host-virus interactions, and the development of novel therapeutic strategies for both infectious diseases and cancer. Ongoing research in this field aims to harness the potential of defective viruses for targeted and innovative medical interventions.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey